2 active not recruiting, 2 recruiting, 1 terminated, 1 withdrawn. 4 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Active not recruiting 2, Recruiting 2 |
| Phase 2 | 3 | Recruiting 1, Terminated 1, Withdrawn 1 |
Follow Hafnium Oxide-containing Nanoparticles NBTXR3: new trials by email Literature Review of Hafnium Oxide-containing Nanoparticles NBTXR3 trials Research Report on Hafnium Oxide-containing Nanoparticles NBTXR3
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase I/II Randomized Study of NBTXR3 Activated by Abscopal or RadScopal Radiation in Combination With Immunotherapy (Anti-PD-1/L-1) for Patients With Advanced Solid Malignancies Hafnium Oxide-containing Nanoparticles NBTXR3, Radiation Therapy - Advanced Malignant Solid Neoplasm, Metastatic Malignant Neoplasm in the Liver | Phase 1 / Phase 2 | Recruiting | M.D. Anderson Cancer Center | 40 | 2023-05-08 | 2026-07-30 |
| NBTXR3, Radiation Therapy, and Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Cancer Hafnium Oxide-containing Nanoparticles NBTXR3, Hypofractionated Radiation Therapy, Pembrolizumab - Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma | Phase 2 | Terminated | M.D. Anderson Cancer Center | 14 | 2021-04-07 | 2026-01-23 |
| Re-irradiation With NBTXR3 in Combination With Pembrolizumab for the Treatment of Inoperable Locoregional Recurrent Head and Neck Squamous Cell Cancer Hafnium Oxide-containing Nanoparticles NBTXR3, Intensity-Modulated Proton Therapy, Intensity-Modulated Radiation Therapy - Recurrent Head and Neck Squamous Cell Carcinoma, Unresectable Head and Neck Squamous Cell Carcinoma | Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2021-03-09 | 2023-09-13 | |
| NBTXR3 and Radiation Therapy for the Treatment of Inoperable Recurrent Non-small Cell Lung Cancer Hafnium Oxide-containing Nanoparticles NBTXR3, Radiation Therapy - Recurrent Lung Non-Small Cell Carcinoma, Stage I Lung Cancer AJCC v8 | Phase 1 | Active not recruiting | M.D. Anderson Cancer Center | 34 | 2021-02-10 | 2026-08-19 |
| NBTXR3, Chemotherapy, and Radiation Therapy for the Treatment of Esophageal Cancer Capecitabine, Carboplatin, Docetaxel - Cervical Esophagus Adenocarcinoma, Clinical Stage II Esophageal Adenocarcinoma AJCC v8 | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 24 | 2020-11-23 | 2026-10-07 |
| NBTXR3 Activated by Radiation Therapy for the Treatment of Locally Advanced or Borderline-Resectable Pancreatic Cancer Hafnium Oxide-containing Nanoparticles NBTXR3, Radiation Therapy - Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Ductal Adenocarcinoma | Phase 1 | Active not recruiting | M.D. Anderson Cancer Center | 24 | 2020-07-01 | 2026-05-22 |
Squamous Cell Carcinoma of Head and Neck (2) · Carcinoma, Non-Small-Cell Lung (1) · Lung Neoplasms (1) · Neoplasm Metastasis (1) · Pancreatic Neoplasms (1)
M.D. Anderson Cancer Center (6)
United States (5)
Eugene J Koay (1) · Jack Phan, MD (1) · Jay Reddy (1) · Saumil Gandhi (1) · Saumil Gandhi, MD (1) · Steven H Lin (1)
P30CA016672 (1)